Cantor Maintains Buy On Celldex Therapeutics Following Data Presentations At SABCS
In a research report issued today, Cantor analyst Mara Goldstein maintained a Buy rating on shares of Celldex Therapeutics (NASDAQ:CLDX) with a $33 price target, following data presentations at the San Antonio Breast Cancer Symposium (SABCS), which took place in San Antonio last week.
Goldstein noted, “Our takeaway view from the conference is that Celldex’s CDX-011, in development for triple negative breast cancer (TNBC), is still very much a contender amongst a number of agents in development for this breast cancer population. We base this on data generated thus far for agents such as Merck’s Keytruda, Roche’s MPDL3280A, and Medivation/Astella’s Xtandi.”
The analyst added, “We like shares of Celldex because of the depth and breadth of candidates in numerous clinical trials and view the opportunities for updates from a number of trials in the near term as potentially accretive to the shares.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Mara Goldstein has a total average return of 18.5% and a 77.1% success rate. Goldstein has a 12.4% average return when recommending CLDX, and is ranked #258 out of 3420 analysts.